{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:56:31Z","timestamp":1791834991202,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s13555-024-01241-w","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T16:17:42Z","timestamp":1722874662000},"page":"2467-2478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Assessing Participants\u2019 Experiences with Vitiligo from Patient Interviews"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-2651","authenticated-orcid":false,"given":"Amit G.","family":"Pandya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9629-1891","authenticated-orcid":false,"given":"Theresa","family":"Amoloja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6871-2333","authenticated-orcid":false,"given":"Kristen","family":"Bibeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2294-9519","authenticated-orcid":false,"given":"Dana","family":"DiBenedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6461-527X","authenticated-orcid":false,"given":"Katherine","family":"Kosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6907-0846","authenticated-orcid":false,"given":"Kathleen","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6286-2069","authenticated-orcid":false,"given":"Deanna","family":"Kornacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-4589","authenticated-orcid":false,"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"issue":"1","key":"1241_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017;77(1):1\u201313.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1241_CR2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"C Kruger","year":"2012","unstructured":"Kruger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol. 2012;51(10):1206\u201312.","journal-title":"Int J Dermatol"},{"issue":"10","key":"1241_CR3","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau K, Pandya AG, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan, and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1241_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","volume":"65","author":"A Alikhan","year":"2011","unstructured":"Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473\u201391.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1241_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757\u201374.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1241_CR6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bjd.15199","volume":"177","author":"YC Lai","year":"2017","unstructured":"Lai YC, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2017;177(3):708\u201318.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1241_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/jdv.14739","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis. J Eur Acad Dermatol Venereol. 2018;32(8):1343\u201351.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1241_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6663646","author":"J Liu","year":"2021","unstructured":"Liu J, Tang R, Xiao Y, et al. Meta-analytic review of high anxiety comorbidity among patients with vitiligo. BioMed Res Int. 2021. https:\/\/doi.org\/10.1155\/2021\/6663646.","journal-title":"BioMed Res Int"},{"issue":"3","key":"1241_CR9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/jdv.16927","volume":"35","author":"VS Narayan","year":"2021","unstructured":"Narayan VS, Uitentuis SE, Luiten RM, Bekkenk MW, Wolkerstorfer A. Patients\u2019 perspective on current treatments and demand for novel treatments in vitiligo. J Eur Acad Dermatol Venereol. 2021;35(3):744\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1241_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000275657","volume":"220","author":"MA Radtke","year":"2010","unstructured":"Radtke MA, Schafer I, Gajur AI, Augustin M. Clinical features and treatment outcomes of vitiligo from the patients\u2019 perspective: results of a national survey in Germany. Dermatology (Basel, Switzerland). 2010;220(3):194\u2013200.","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"15","key":"1241_CR11","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317.","journal-title":"Blood"},{"key":"1241_CR12","unstructured":"Opzelura\u2122 (ruxolitinib cream). Full prescribing information, Incyte Corporation, Wilmington, DE, 2023."},{"key":"1241_CR13","unstructured":"Opzelura\u2122 (ruxolitinib cream). Summary of product characteristics, Incyte Biosciences Distribution B.V., Amsterdam, Netherlands, 2023."},{"key":"1241_CR14","unstructured":"OpzeluraTM. (ruxolitinib cream). Summary of product characteristics, Incyte Biosciences UK Ltd, Leatherhead, UK, 2023."},{"key":"1241_CR15","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387:1445\u201355.","journal-title":"N Engl J Med"},{"issue":"8","key":"1241_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2014eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"issue":"1","key":"1241_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijwd.2017.11.005","volume":"4","author":"PE Grimes","year":"2018","unstructured":"Grimes PE, Miller MM. Vitiligo: patient stories, self-esteem, and the psychological burden of disease. Int J Womens Dermatol. 2018;4(1):32\u20137.","journal-title":"Int J Womens Dermatol"},{"issue":"8","key":"1241_CR18","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s13555-022-00772-4","volume":"12","author":"H Kitchen","year":"2022","unstructured":"Kitchen H, Gandhi K, Carmichael C, et al. A qualitative study to develop and evaluate the content validity of the vitiligo patient priority outcome (ViPPO) measures. Dermatol Ther (Heidelb). 2022;12(8):1907\u201324.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"1241_CR19","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s13555-022-00752-8","volume":"12","author":"H Kitchen","year":"2022","unstructured":"Kitchen H, Wyrwich KW, Carmichael C, et al. Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the Vitiligo Area Scoring Index (VASI). Dermatol Ther (Heidelb). 2022;12(7):1623\u201337.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1241_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/bjd.17013","volume":"180","author":"V Eleftheriadou","year":"2019","unstructured":"Eleftheriadou V, Hamzavi I, Pandya AG, et al. International initiative for outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation. Br J Dermatol. 2019;180(3):574\u20139.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1241_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1365-2230.2009.03765.x","volume":"35","author":"N Talsania","year":"2010","unstructured":"Talsania N, Lamb B, Bewley A. Vitiligo is more than skin deep: a survey of members of the Vitiligo Society. Clin Exp Dermatol. 2010;35(7):736\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1241_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/bjd\/ljad109","volume":"189","author":"S Merhi","year":"2023","unstructured":"Merhi S, Salameh P, Abboud M, et al. Face involvement is reflective of global perception of extent in vitiligo patients. Br J Dermatol. 2023;189(2):188\u201394.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1241_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bjd.21671","volume":"187","author":"JM Batchelor","year":"2022","unstructured":"Batchelor JM, Gran S, Leighton P, et al. Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability. Br J Dermatol. 2022;187(4):548\u201356.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1241_CR24","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1524-4733.2009.00603.x","volume":"12","author":"M Rothman","year":"2009","unstructured":"Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value Health. 2009;12(8):1075\u201383.","journal-title":"Value Health"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01241-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01241-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01241-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T08:43:16Z","timestamp":1726130596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01241-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01241-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amit G. Pandya has served as an investigator for Aclaris Therapeutics, Immune Tolerance Network, Incyte Corporation, and Pfizer and a consultant for AbbVie, Arcutis, Avita Medical, Immune Tolerance Network, Incyte Corporation, Pfizer, Thalocan, TWi, Viela Bio, Vimela, Villaris, Vyne and WCG\/Trifecta, and holds stock options for Tara Medical and Zerigo Health. Theresa Amoloja and Deanna Kornacki are employees and shareholders of Incyte Corporation. Kristen Bibeau (currently an employee at Moderna) and Kathleen Butler (currently an employee at Astria Therapeutics) were employees of Incyte Corporation at the time of the study and are shareholders of Incyte Corporation. Dana DiBenedetti and Katherine Kosa are employees of RTI Health Solutions, which was contracted by Incyte Corporation to conduct interviews with participants identified by a recruiting firm (Study 2). Khaled Ezzedine is a consultant for AbbVie, Incyte Corporation, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The TRuE-V1\/TRuE-V2 study protocols (Study 1) were approved by the Western Institutional Review Board and an institutional review board or ethics committee at participating centers. Trials were conducted in accordance with the Declaration of Helsinki and adhered to study protocols, Good Clinical Practice, and applicable country-specific laws and regulations. Written informed consent or assent was provided by all patients. Study 2 was performed in accordance with the Declaration of Helsinki and in adherence to the study protocol and local regulatory requirements. Prior to the start of each interview, participants provided verbal informed consent (for adult interviewees) or assent with parental permission (for adolescent participants) and could withdraw consent at any time. The study protocol was approved by the RTI Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors thank the patients and their families for their participation in the TRuE-V1 and TRuE-V2 studies, including those who agreed to be interviewed for Study 1, and the individuals who participated in the interviews in Study 2.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participants"}}]}}